Deal-starved banks lined up to make concessions to get a slice of Europe’s biggest buyout debt deal last year. They also put ...

In 2025, Sanofi will receive a cash consideration in the high single-digits in billions in euros from the Opella transaction at the earliest in Q2 while retaining a significant stake in the ...

Sanofi has plans to separate its Consumer Healthcare [“CHC”] unit through the creation of a publicly listed entity headquartered in Paris called Opella. Sanofi intends to sell a controlling ...

The sale of Sanofi's controlling stake in consumer health business Opella is expected to close in the second quarter at the earliest, completing its transition into a pure-play drug and vaccine ...

Sanofi also said it would launch a buyback of up to 5 billion euros ($5.21 billion) in 2025, stemming from plans to sell a controlling stake in its Opella consumer health business, which the ...

The sale of Sanofi's controlling stake in consumer health business Opella is expected to close in the second quarter at the earliest, completing its transition into a pure-play drug and vaccine ...

Sanofi said it plans to launch a $5.2 Bln share ... stemming from the exit of its consumer health business Opella. For 2025, the company expects its sales to grow mid-to-high single digit at ...

Intention to sell a controlling stake in Opella consumer health at an attractive ... performing stocks on TipRanks >> Read More on SNY: Sanofi NewsMORE Related Stocks Indices Commodities ...